Healthcare provider profile · identity verified

Amber Galey, MD

Family Practice · ESTES PARK, CO · NPI 1699185801

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	327	98
Losartan Potassium	Losartan Potassium	164	47
Omeprazole	Omeprazole	151	45
Levothyroxine Sodium	Levothyroxine Sodium	142	39
Rosuvastatin Calcium	Rosuvastatin Calcium	109	34
Sertraline Hcl	Sertraline Hcl	109	27
Lisinopril	Lisinopril	108	35
Amlodipine Besylate	Amlodipine Besylate	106	33
Hydrochlorothiazide	Hydrochlorothiazide	91	25
Alendronate Sodium	Alendronate Sodium	84	28
Pantoprazole Sodium	Pantoprazole Sodium	75	20
Simvastatin	Simvastatin	74	22
Metformin Hcl	Metformin Hcl	69	19
Metoprolol Succinate	Metoprolol Succinate	69	22
Gabapentin	Gabapentin	62	16
Ozempic	Semaglutide	60	suppressed
Meloxicam	Meloxicam	58	13
Fluoxetine Hcl	Fluoxetine Hcl	52	13
Trazodone Hcl	Trazodone Hcl	46	15
Pravastatin Sodium	Pravastatin Sodium	43	14
Tamsulosin Hcl	Tamsulosin Hcl	41	suppressed
Metformin Hcl Er	Metformin Hcl	38	15
Albuterol Sulfate Hfa	Albuterol Sulfate	33	16
Famotidine	Famotidine	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	30	suppressed
Mirtazapine	Mirtazapine	30	suppressed
Furosemide	Furosemide	29	suppressed
Xarelto	Rivaroxaban	29	suppressed
Potassium Chloride	Potassium Chloride	28	suppressed
Glimepiride	Glimepiride	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Fluticasone Propionate	Fluticasone Propionate	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Carvedilol	Carvedilol	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Lovastatin	Lovastatin	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Finasteride	Finasteride	19	suppressed
Eliquis	Apixaban	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Acyclovir	Acyclovir	14	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Prednisone	Prednisone	14	13
Risperidone	Risperidone	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Atenolol	Atenolol	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	13	suppressed
Nystatin	Nystatin	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Estradiol	Estradiol	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Olanzapine	Olanzapine	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Baclofen	Baclofen	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Cimetidine	Cimetidine	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Glipizide	Glipizide	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error